Literature DB >> 20533527

Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly.

Kim L McBride1, Elizabeth A Varga, Matthew T Pastore, Thomas W Prior, Kandamurugu Manickam, Joan F Atkin, Gail E Herman.   

Abstract

There is a strong genetic component to autism spectrum disorders (ASD), but due to significant genetic heterogeneity, individual genetic abnormalities contribute a small percentage to the overall total. Previous studies have demonstrated PTEN mutations in a sizable proportion of individuals with ASD or mental retardation/developmental delays (MR/DD) and macrocephaly that do not have features of Cowden or Bannayan-Riley-Ruvalcaba syndrome. This study was performed to confirm our previous results. We reviewed the charts of individuals who had PTEN clinical sequencing performed at our institution from January 2008 to July 2009. There were 93 subjects tested from our institution during that period. PTEN mutations were found in 2/39 (5.1%) ASD patients and 2/51 (3.9%) MR/DD patients. Three additional patients without mutations had no diagnostic information. Multiple relatives of individuals with a PTEN mutation had macrocephaly, MR, or early onset cancer (breast, renal, and prostate). Of those relatives tested, all had the familial PTEN mutation. None of the affected relatives had previously been diagnosed with Cowden or Bannayan-Riley-Ruvalcaba syndrome. We noted in our previous study several adult relatives without any findings who carried a mutation. Combined with data from our previous cohort, we have found PTEN mutations in 7/99 (7.1%) of individuals with ASD and 8/100 (8.0%) of individuals with MR/DD, all of whom had macrocephaly. We recommend testing for mutations in PTEN for individuals with ASD or MR/DD and macrocephaly. If mutations are found, other family members should be offered testing and the adults offered cancer screening if they have a PTEN mutation.

Entities:  

Mesh:

Year:  2010        PMID: 20533527     DOI: 10.1002/aur.132

Source DB:  PubMed          Journal:  Autism Res        ISSN: 1939-3806            Impact factor:   5.216


  105 in total

1.  Clinical and laboratory data in a sample of Greek children with autism spectrum disorders.

Authors:  Athina Ververi; Efthymia Vargiami; Vassiliki Papadopoulou; Dimitrios Tryfonas; Dimitrios I Zafeiriou
Journal:  J Autism Dev Disord       Date:  2012-07

2.  Phosphatase and tensin homologue (PTEN) regulates synaptic plasticity independently of its effect on neuronal morphology and migration.

Authors:  Margaret Sperow; Raymond B Berry; Ildar T Bayazitov; Guo Zhu; Suzanne J Baker; Stanislav S Zakharenko
Journal:  J Physiol       Date:  2011-12-06       Impact factor: 5.182

3.  The viral theory of schizophrenia revisited: abnormal placental gene expression and structural changes with lack of evidence for H1N1 viral presence in placentae of infected mice or brains of exposed offspring.

Authors:  S Hossein Fatemi; Timothy D Folsom; Robert J Rooney; Susumu Mori; Tess E Kornfield; Teri J Reutiman; Rachel E Kneeland; Stephanie B Liesch; Kegang Hua; John Hsu; Divyen H Patel
Journal:  Neuropharmacology       Date:  2011-01-26       Impact factor: 5.250

Review 4.  Regulation of recombination and genomic maintenance.

Authors:  Wolf-Dietrich Heyer
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-08-03       Impact factor: 10.005

5.  PI3K isoform-selective inhibition in neuron-specific PTEN-deficient mice rescues molecular defects and reduces epilepsy-associated phenotypes.

Authors:  Angela R White; Durgesh Tiwari; Molly C MacLeod; Steve C Danzer; Christina Gross
Journal:  Neurobiol Dis       Date:  2020-07-24       Impact factor: 5.996

Review 6.  Long noncoding RNA and its contribution to autism spectrum disorders.

Authors:  Jie Tang; Yizhen Yu; Wei Yang
Journal:  CNS Neurosci Ther       Date:  2017-06-20       Impact factor: 5.243

7.  A Saturation Mutagenesis Approach to Understanding PTEN Lipid Phosphatase Activity and Genotype-Phenotype Relationships.

Authors:  Taylor L Mighell; Sara Evans-Dutson; Brian J O'Roak
Journal:  Am J Hum Genet       Date:  2018-04-26       Impact factor: 11.025

Review 8.  Balancing Proliferation and Connectivity in PTEN-associated Autism Spectrum Disorder.

Authors:  Amanda K Tilot; Thomas W Frazier; Charis Eng
Journal:  Neurotherapeutics       Date:  2015-07       Impact factor: 7.620

Review 9.  The role of phosphoinositides in synapse function.

Authors:  Yoshibumi Ueda
Journal:  Mol Neurobiol       Date:  2014-06-17       Impact factor: 5.590

Review 10.  Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.

Authors:  Jeffrey P MacKeigan; Darcy A Krueger
Journal:  Neuro Oncol       Date:  2015-08-19       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.